Literature DB >> 20661669

Detection and treatment of resistant hypertension.

Julian Segura1, Alejandro de la Sierra, Luis M Ruilope.   

Abstract

The evaluation of patients with resistant hypertension should be directed toward confirming true treatment resistance, identifying the causes contributing to treatment resistance (including secondary causes of hypertension), and documenting target-organ damage. Treatment of resistant hypertension is aimed at reversing lifestyle factors contributing to treatment resistance, accurately diagnosing and appropriately treating secondary causes of hypertension, and effectively using multidrug regimens. Lifestyle changes, pharmacologic therapies, and nonpharmacologic therapies have all shown benefits in patients with resistant hypertension, but much additional knowledge is needed to better identify and treat these patients.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20661669     DOI： 10.1007/s11906-010-0136-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


  29 in total

1.  Urinary albumin excretion is associated with true resistant hypertension.

Authors:  A Oliveras; P Armario; R Hernández-Del Rey; J A Arroyo; E Poch; M Larrousse; A Roca-Cusachs; A de la Sierra
Journal:  J Hum Hypertens       Date:  2010-01       Impact factor: 3.012

2.  Modest salt reduction lowers blood pressure in isolated systolic hypertension and combined hypertension.

Authors:  Feng J He; Nirmala D Markandu; Graham A MacGregor
Journal:  Hypertension       Date:  2005-06-13       Impact factor: 10.190

3.  Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity.

Authors:  Gary L Schwartz; Stephen T Turner
Journal:  Clin Chem       Date:  2005-02       Impact factor: 8.327

4.  Differential control of systolic and diastolic blood pressure : factors associated with lack of blood pressure control in the community.

Authors:  D M Lloyd-Jones; J C Evans; M G Larson; C J O'Donnell; E J Roccella; D Levy
Journal:  Hypertension       Date:  2000-10       Impact factor: 10.190

5.  Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research.

Authors:  Thomas G Pickering; John E Hall; Lawrence J Appel; Bonita E Falkner; John Graves; Martha N Hill; Daniel W Jones; Theodore Kurtz; Sheldon G Sheps; Edward J Roccella
Journal:  Circulation       Date:  2005-02-08       Impact factor: 29.690

6.  Projected effect of dietary salt reductions on future cardiovascular disease.

Authors:  Kirsten Bibbins-Domingo; Glenn M Chertow; Pamela G Coxson; Andrew Moran; James M Lightwood; Mark J Pletcher; Lee Goldman
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

7.  A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines.

Authors:  Anna M Sawka; Roman Jaeschke; Ravinder J Singh; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

Review 8.  Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.

Authors:  Bernard Waeber; François Feihl; Luis M Ruilope
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

10.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.